Explore our free mid-revenue cycle articles and webinars here.

Ask a Rev Cycle Expert: COVID-19 Monoclonal Antibody Administration?

Question:

Can the COVID-19 monoclonal antibody treatments, i.e. casirivimab/imdevimab or bamlanivimab/etesevimab, be provided to a patient admitted with COVID-19?

Answer:

The emergency use authorization (EUA) issued by the U.S. Food & Drug Administration (FDA), the monoclonal antibody therapies are for use on an outpatient basis to treat mild-to-moderate COVID-19 patients. The EUA specifically states that monoclonal antibodies are not authorized for use in patients who are hospitalized due to COVID-19.

Disclaimer: This information was current at the time of its publishing and is designed to provide accurate information in regard to the subject matter covered. Vitalware does not accept any responsibility or liability with regard to any errors, omissions, misuses, or misinterpretation by the reader. It is not intended to take the place of either the written policies or regulations. We encourage you to review the specific regulations and other interpretive materials as necessary. All CPT® codes are trademarked by the American Medical Association (AMA) and all revenue codes are copyrighted by the American Hospital Association (AHA).